Clinical Trial Update: A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia [Phase 2]

View source ↗

Summary

Phase IIa withdrawal study of CNV1014802 in trigeminal neuralgia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Trigeminal Neuralgia

Drugs mentioned

• CNV1014802

Snippet

Sponsor: Biogen | Conditions: Trigeminal Neuralgia | Phase 2 | Status: COMPLETED